After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The company reported better-than-expected earnings and revenue Friday.
The company's hepatitis C drug division is expected to see losses in the second half of the year.
Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.
Bristol-Myers (BMY) reported 2016 second-quarter financial results that beat estimates before the market open.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.